Advances in the Development of SARS-CoV-2 Mpro Inhibitors
View/ Open
Impact
Scholar |
Other documents of the author: Agost Beltrán, Laura; de la hoz rodriguez, Sergio; Bou Iserte, Lledó; Rodríguez, Santiago; Fernández de la Pradilla Ibáñez, Adrián; González, Florenci
Metadata
Show full item recordcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/7053
comunitat-uji-handle3:10234/8639
comunitat-uji-handle4:
INVESTIGACIONMetadata
Title
Advances in the Development of SARS-CoV-2 Mpro InhibitorsAuthor (s)
Date
2022-04-14Publisher
MDPIISSN
1420-3049Bibliographic citation
Agost-Beltrán, L.; de la Hoz-Rodríguez, S.; Bou-Iserte, L.; Rodríguez, S.; Fernández-de-la-Pradilla, A.; González, F.V. Advances in the Development of SARS-CoV-2 Mpro Inhibitors. Molecules 2022, 27, 2523. https://doi.org/10.3390/molecules 27082523Type
info:eu-repo/semantics/articleVersion
info:eu-repo/semantics/publishedVersionSubject
Abstract
Since the outbreak of COVID-19, one of the strategies used to search for new drugs has been
to find inhibitors of the main protease (Mpro) of the virus SARS-CoV-2. Initially, previously reported
inhibitors of related ... [+]
Since the outbreak of COVID-19, one of the strategies used to search for new drugs has been
to find inhibitors of the main protease (Mpro) of the virus SARS-CoV-2. Initially, previously reported
inhibitors of related proteases such as the main proteases of SARS-CoV and MERS-CoV were tested.
A huge effort was then carried out by the scientific community to design, synthesize and test new
small molecules acting as inactivators of SARS-CoV-2 Mpro. From the chemical structure view, these
compounds can be classified into two main groups: one corresponds to modified peptides displaying
an adequate sequence for high affinity and a reactive warhead; and the second is a diverse group
including chemical compounds that do not have a peptide framework. Although a drug including a
SARS-CoV-2 main protease inhibitor has already been commercialized, denoting the importance of
this field, more compounds have been demonstrated to be promising potent inhibitors as potential
antiviral drugs. [-]
Is part of
Molecules, Vol. 27, Iss. 8 (April-2 2022)Funder Name
Universitat Jaume I | Ministerio de Universidades
Project code
UJI‐2021-71 | FPU19/04913 | FPU17/06209 | FPU20/03516
Project title or grant
SomUJIContraCovid
Rights
info:eu-repo/semantics/openAccess
This item appears in the folowing collection(s)
- QFA_Articles [817]
- QUIO_Articles [694]
Except where otherwise noted, this item's license is described as Copyright: © 2022 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).